Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin With or Without Antidepressants in Treating Hot Flashes in Women Who Have Had Breast Cancer or Have Concerns About Taking Hormone Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* History of breast cancer OR a concern about taking hormonal therapy due to a fear of developing breast cancer~* Experiencing bothersome hot flashes, defined as patient-reported occurrence ≥ 14 times per week AND sufficiently severe to prompt desire for additional therapeutic intervention despite current use of an antidepressant~  * Currently (≥ 2 weeks) being treated with a stable dose of an antidepressant~    * No monoamine oxidase inhibitors or tricyclics~* No current evidence of malignant disease~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age~* 18 and over~Sex~* Female~Performance status~* ECOG 0-1~Life expectancy~* At least 6 months~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective barrier contraception~PRIOR CONCURRENT THERAPY:~Chemotherapy~* More than 4 weeks since prior antineoplastic chemotherapy~* No concurrent antineoplastic chemotherapy~Endocrine therapy~* More than 4 weeks since prior androgens, estrogens, or progestational agents~* More than 2 weeks since prior dehydroepiandrosterone (DHEA) for treatment of hot flashes~* No concurrent androgens, estrogens, or progestational agents, including oral contraceptives~* No concurrent DHEA for treatment of hot flashes~* Concurrent tamoxifen, raloxifene, or aromatase inhibitor therapy allowed if on a stable dose for at least 4 weeks prior to study entry and during study treatment~Other~* No prior gabapentin~* More than 2 weeks since other prior treatment for hot flashes (e.g., clonidine or Bellergal-S®)~* Concurrent vitamin E or soy supplements allowed if on a stable dose for at least 1 month prior to study entry and during study treatment~* No other concurrent treatment for hot flashes (e.g., clonidine or Bellergal-S®)~* No other concurrent antidepressants

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- gabapentin + antidepressant (Type: EXPERIMENTAL): Patients continue to receive the same antidepressant (as before study entry) on weeks 1-5. During weeks 2-5, patients also receive oral gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity.~Patients complete a hot flash diary at baseline and then daily during study treatment.
- gabapentin (Type: EXPERIMENTAL): Patients receive gabapentin once daily on days 8-10, twice daily on days 11-13, and then three times daily on days 14-35 in the absence of unacceptable toxicity. Patients are tapered off their antidepressant over 7-10 days and remain on gabapentin alone.~Patients complete a hot flash diary at baseline and then daily during study treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).